Core Viewpoint - Rapid Micro Biosystems, Inc. is set to release its second quarter 2025 financial results on August 12, 2025, prior to market opening, indicating a focus on transparency and communication with investors [1]. Company Overview - Rapid Micro Biosystems is a life sciences technology company that provides automation solutions aimed at improving the manufacturing and release processes of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables [3]. - The company's flagship product, the Growth Direct system, modernizes microbial quality control (MQC) testing workflows, enhancing operational efficiency and compliance with data integrity regulations [3]. - The company is headquartered in Lexington, Massachusetts, with manufacturing facilities in Lowell, Massachusetts, and additional global locations in Switzerland, Germany, and the Netherlands [3]. Upcoming Events - The management team will host a webcast conference call on August 12, 2025, at 8:30 a.m. ET, providing an opportunity for stakeholders to engage with the company's leadership [2]. - The live audio webcast will be available on the company's website and will be archived for later access [2].

Core Viewpoint - CubeSmart reported stable operating fundamentals with modest improvements in seasonal performance compared to the previous year, driven by reduced new supply and better pricing strategies for new customers [2][3]. Financial Results - Net income attributable to common shareholders for Q2 2025 was $83.0 million, down from $94.0 million in Q2 2024, with diluted EPS decreasing to $0.36 from $0.41 [3][8]. - Adjusted FFO for Q2 2025 was $148.9 million, slightly up from $146.0 million in Q2 2024, with FFO per diluted share increasing by 1.6% to $0.65 [4][40]. Investment Activity - No acquisitions were made in Q2 2025, but the company acquired an 80% interest in HVP IV for $452.8 million, which included repayment of $44.4 million of existing debt [5][6]. - The company has two joint venture development properties under construction, with a total anticipated investment of $36.9 million, of which $27.0 million has been invested as of June 30, 2025 [6]. Same-Store Results - The same-store portfolio included 606 stores with a net operating income (NOI) decrease of 1.1% year-over-year, attributed to a 0.5% decline in revenues and a 1.2% rise in operating expenses [8][9]. - Same-store occupancy averaged 90.6% during the quarter, ending at 91.1%, compared to 91.8% in the previous year [9][41]. Operating Results - Total consolidated portfolio as of June 30, 2025, included 659 stores with 48.1 million rentable square feet and a physical occupancy of 90.8% [10][11]. - Total revenues increased by $16.1 million, while property operating expenses rose by $5.9 million compared to Q2 2024, primarily due to acquisitions and new developments [11][12]. Financing Activity - Interest expense increased to $29.1 million in Q2 2025 from $22.8 million in Q2 2024, driven by a higher average outstanding debt balance and increased interest rates [12][13]. Quarterly Dividend - A quarterly dividend of $0.52 per common share was declared on May 20, 2025, and paid on July 15, 2025 [14]. 2025 Financial Outlook - The company estimates fully diluted EPS for 2025 to be between $1.44 and $1.50, and adjusted FFO per share to be between $2.54 and $2.60 [15][16].

Core Insights - Certara, Inc. has appointed Christopher Bouton, Ph.D., as Chief Technology Officer to lead the development of a next-generation integrated model-informed drug development platform utilizing generative AI and advancements in biosimulation technology [1][4] Company Overview - Certara is a global leader in model-informed drug development, providing biosimulation software, technology, and services to enhance traditional drug discovery and development processes [5] - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries [5] Leadership and Innovation - Dr. Bouton, previously the founder and CEO of Vyasa Analytics, has a strong background in AI and drug development, having led the creation of several AI-based products at Certara [2][3] - His leadership is expected to enhance the adoption of AI-powered biosimulation and virtual trials, improving the efficiency of bringing new medicines to market [3][5] Technological Advancements - The integration of biosimulation with generative AI and machine learning is transforming the drug discovery and development landscape, leading to faster timelines, reduced costs, and improved success rates [5]

Core Insights - iRhythm Technologies has formed a strategic partnership with Lucem Health to enhance early detection of undiagnosed arrhythmias in high-risk patient populations [1][2][3] - The collaboration aims to shift from reactive to proactive healthcare, utilizing AI to identify arrhythmia risks before symptoms manifest [2][3] - The partnership targets over 27 million individuals in the U.S. who could benefit from proactive cardiac monitoring [2][8] Company Overview - iRhythm Technologies is a digital health leader focused on solutions that detect, predict, and prevent disease, utilizing wearable biosensors and cloud-based analytics [18] - Lucem Health specializes in AI-driven early disease detection, aiming to improve clinical outcomes and resource allocation in healthcare [19] Partnership Details - The collaboration will leverage Lucem Health's AI platform and iRhythm's diagnostic services to enable earlier identification of arrhythmia risks [2][3] - The first commercial offering will focus on patients with conditions like Type 2 diabetes, chronic kidney disease, chronic obstructive pulmonary disease, and coronary artery disease [4][6] Clinical Impact - Early pilot testing indicates improved targeting of patient populations at risk for arrhythmias, facilitating earlier clinical engagement [7] - The predictive AI solution is expected to enhance arrhythmia detection among an estimated 27 million undiagnosed patients in the U.S., potentially reducing healthcare resource utilization and costs [8][15] Economic Considerations - Cardiac arrhythmias affect approximately 1 in 20 U.S. adults, and untreated cases can lead to severe health complications, emphasizing the need for early detection [9][11] - Research shows that patients with arrhythmias incur significantly higher healthcare costs, reinforcing the economic case for earlier detection and intervention [13][14]

FREMONT, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX, ENVXW) (“Enovix”), a global high-performance battery company, announced that it posted on its website here a letter to shareholders from President and CEO, Dr. Raj Talluri, and CFO, Ryan Benton, discussing the company’s second quarter 2025 results. The company will host a live webcast at 5:00 PM ET / 2:00 PM PT to discuss the results and provide business updates. To register for the webcast, please visit: https://enovix-q2- ...

GUANGZHOU, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- YSX TECH. CO., LTD (the “Company,” “our,” “us” or “YSXT”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced its financial results for the fiscal year ended March 31, 2025. Key Financial Metrics for Fiscal Year 2025 Total revenue grew by approximately 22.0% to approximately $71.5 million in the fiscal year ...

Second Quarter Results Total revenues of $36.5 million, a 23% year-over-year improvementNet income of $0.9 million and diluted earnings per share of $0.34, which includes a positive impact of $1.4 million related to the release of our deferred tax valuation allowance in CanadaAdjusted EBITDA of $2.2 million, a $1.3 million year-over-year improvement $25.4 million in cash and $7.7 million of total debt as of June 30, 2025 HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. (Nasdaq: NCSM) ...

WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. T ...

Core Insights - Stryker reported a consolidated net sales of $6.0 billion for Q2 2025, reflecting an 11.1% increase compared to the previous year, with organic net sales growing by 10.2% [2][14][24] - The company experienced strong growth in its MedSurg and Neurotechnology segments, with net sales increasing by 17.3% to $3.8 billion, while Orthopaedics saw a modest growth of 2.0% to $2.2 billion [2][3][24] - Adjusted net earnings for the quarter reached $1.2 billion, marking an 11.6% increase, with adjusted earnings per diluted share rising to $3.13, up 11.4% [4][14][24] Sales Performance - Total net sales growth was driven by a combination of increased unit volume and higher prices, with organic net sales growth of 10.2% attributed to 9.7% from unit volume and 0.5% from price increases [2][24] - MedSurg and Neurotechnology segment's organic net sales increased by 11.0%, while Orthopaedics' organic net sales grew by 9.0% [2][3][24] - The U.S. market contributed significantly, with reported sales of $4.6 billion, reflecting a 12.5% increase, while international sales grew by 6.8% [24][28] Earnings Analysis - Reported net earnings for the quarter were $884 million, a 7.2% increase, with a diluted earnings per share of $2.29, up 7.0% [4][14][24] - Adjusted gross profit margin was reported at 65.4%, while adjusted operating income margin increased to 25.7%, up 110 basis points [4][14][24] - The company raised its full-year 2025 guidance, expecting organic net sales growth of 9.5% to 10.0% and adjusted net earnings per diluted share in the range of $13.40 to $13.60 [5][6] Market Outlook - Stryker anticipates a modestly favorable pricing impact and a slight positive effect from foreign exchange rates on sales and adjusted net earnings per diluted share [6][7] - The estimated net impact from tariffs in 2025 is approximately $175 million, reflecting recent updates in trade policies [7]

SAN JOSE, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the second quarter of fiscal year 2026 on Thursday, August 21, 2025, after the market closes. A live Zoom Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.com. A replay will be available approximately two hours after the conclusion of the live event. About ZoomZoom’s mission is t ...